

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.

AUD 275-107
AU 24 2001
TECH CENTER 1600/2200
FILED

In re patent application of

Theoharis C. Theoharides

Serial No. 09/771,669

GAU: 1615

Filed: 1/30/2001

Examiner: TBA

For : Synergistic Proteoglycan Compositions for Inflammatory Conditions

TRANSMITTAL

Assistant Commissioner for Patents

Washington, D.C. 20231

BOX NON-FEE PRELIMINARY AMENDMENT

Sir:

Transmitted herewith is a Preliminary Amendment in the above-captioned application. The fee has been re-calculated as shown below. (*Small entity fees indicated in parentheses.*)


CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
Total Claims <i>(Small Entity)</i>	27	-	27	0	18.00 <i>(9.00)</i>	0
Independent claims <i>(Small Entity)</i>	1	-	3	0	80.00 <i>(40.00)</i>	0
Multiple Dependent <i>(Small Entity)</i>	0	-	0	0	270.00 <i>(135.00)</i>	0
Extension of Time	One Month		Two Months	Three Months		
Fee	\$110 <i>(\$55)</i>		\$390 <i>(\$195)</i>	\$890 <i>(\$445)</i>		0
Total						50

Date: 08/03/2001

Law Offices of Dr. Melvin Blecher
4329 Van Ness Street, NW
Washington, DC 20016-5625
202-363-3338

Respectfully submitted,
Melvin Blecher

Melvin Blecher, PhD
Attorney-at-Law
Reg. No. 33649



Attorney Dkt. No. 51275/107

TECH 1615
INTER 1615
JULY 24 2001
Group Art Unit: 1615
Examiner: TBA

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: application of:

Theoharis C. Theoharides

Serial No. 09/771,669

Filed: 01/30/2001

For: Synergistic Proteoglycan Compositions For Inflammatory Conditions

PRELIMINARY AMENDMENT

#41B

AKD

8-29-01

Assistant Commissioner for Patents
Washington, DC 20231
BOX NON-FEE AMENDMENT

Sir:

Prior to examination, please amend the title and the claims, delete claims, and add new claims as follows:

In The Title

Please amend the title to that shown in the caption.

In The Claims (Clean Copy)

B1
SUB
D1

1. A composition with synergistic anti-inflammatory properties for use in human conditions induced by inflammatory biomolecules released from mast cells by the activation and degranulation of mast cells, comprising a non-bovine proteoglycan and one or more of a hexosamine sulfate, a flavonoid, S-adenosylmethionine, a histamine-1-receptor antagonist, and kernel olive oil, in an appropriate excipient or vehicle for oral or topical administration.
2. The composition according to claim 1, wherein said proteoglycan is selected from the group consisting of non-bovine chondroitin sulfate, keratan sulfate, dermatan sulfate and hyaluronic acid.
3. The composition according to claim 2, wherein said chondroitin sulfate is derived from shark cartilage.
4. The composition according to claim 1, wherein said hexosamine sulfate is D-glucosamine sulfate.
5. The composition according to claim 1, wherein said flavonoid is selected from the group consisting of quercetin, myricetin, genistein and kaempferol.



08-22-09

GAU 1615

TECH CENTER 1600

AUG 24 2001

RECEIVED

Attorney Dkt. No. 51275/1075/1075

Group Art Unit 1615
Examiner: TBA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: application of:
Theoharis C. Theoharides
Serial No. 09/771,669
Filed: 01/30/2001
For: Synergistic Proteoglycan Compositions For Inflammatory Conditions

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, DC 20231
BOX NON-FEE PRELIMINARY AMENDMENT

Sir:

In response to a communication mailed by the Office on August 16, 2001 regarding a Preliminary Amendment filed by applicant on August 3, 2001, said to be non-compliant under revised 37 CFR 1.121, applicant is re-submitting within the 30-day response period an amended Preliminary Amendment that is now compliant with the revised rule.

Respectfully submitted,

Melvin Blecher, PhD
Attorney-at-Law
Reg. No. 33,649

Law Offices of Dr. Melvin Blecher
4329 Van Ness St., NW
Washington, DC 20016-5625
Tel: 202-363-3338
FAX 202-362-8404

CERTIFICATE OF MAILING:

I hereby certify that this correspondence is being deposited on August 21, 2001 with the U.S. Postal Service as (first class mail)(Express Mail No. EF315358676US) in an envelop addressed to Assistant Commissioner for Patents, Box: Non-Fee Amendment, Washington, D.C. 20231.

Melvin Blecher, Ph.D.
Registration No. 33,649